LimmaTech Biologics

1:15 PM - 1:30 PM, Tuesday, June 4, 2019 ・ Theater 4
LimmaTech Biologics is an early-stage company based in Switzerland. We are developing a novel expression platform – the Custom Glycan Platform - for the manufacturing of first-in-class therapeutic glycoproteins. The Custom Glycan Platform enables fast, robust and simple production of proteins with tailored and homogenous glycosylation patterns. This allows to obtain more safe and efficacious products. We are currently focusing on monoclonal antibodies which thanks to the glycan profile will be better clinical outcomes.
Ticker:
Not Provided.
Exchange:
Not Provided.
Company Type:
Company Website:
Company HQ State:
Not Provided.
Company HQ Country:
Switzerland
Year Founded:
2016
Main Therapeutic Focus:
Lead Product in Development:
anti-TNF
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided.
Speaker
photo
CEO
LimmaTech Biologics